M alfunctioning of the enzyme CDK7 is crucial to many cancers, making drugs that target it a high priority. Despite some demonstrated success, the mechanism by which these drugs work has been a ...

Cancer drugs that inhibit CDK7 rapidly shut down pathways responsible for cell proliferation within minutes. For organs to ...

In recent years, several companies have developed CDK7 inhibitors that—in clinical trials—have worked to slow tumor growth. But it's not entirely clear how they do this. The drugs have serious ...

The research shows that novel cancer drugs designed to inhibit CDK7 can, within minutes, shut down gene expression pathways that drive cell proliferation in dozens of different kinds of tissues.

Other companies that have taken MALT1-targeting drugs into clinical trials for cancer ... Exscientia’s current clinical-stage pipeline consists of CDK7 inhibitor GTAEXS-617, which is co-owned ...

To protect its technology and pipeline, BioTheryX has an impressive patent portfolio with approximately 85% of its 2,500-plus drug-like compound ... programs target CDK7/9, GSPT1, CK1a, IKAROS ...

RXRX's CDK7 inhibitor REC-617 has demonstrated activity but additional data from the ELUCIDATE trial in various solid tumors isn't expected until H2'25. Near-term catalysts include phase 2 TUPELO ...

for her studies on CDK7 and CDK9. Congratulations Olivia! (August 2020) The Young lab (MIT) and colleagues published a study in Science that shows that clinically relevant drugs selectively partition ...

The research shows that novel cancer drugs designed to inhibit CDK7 can, within minutes, shut down gene expression pathways that drive cell proliferation in dozens of different kinds of tissues.